Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|December 7, 2019
Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir UseMelissa Crawford, Jean van Wyk, Michael Aboud, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.
Antiviral Therapy|April 13, 2017
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb studyBenoît Trottier, Jordan E Lake, Ken Logue, et al.
Antiviral Therapy|September 14, 2017
Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb studyBenoît Trottier, Jordan E Lake, Ken Logue, et al.
British Journal of Clinical Pharmacology|February 5, 2023
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studiesRashmi Mehta, Chakradhar V Lagishetty, Konstantinos Angelis, et al.
The Journal of Antimicrobial Chemotherapy|July 29, 2025
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeksParul Patel, Ana Milinkovic, Richard Grove, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2022
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2Josep M Llibre, Luis Fernando López Cortés, Alicia Aylott, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b studySamit R Joshi, Mar Masiá, Essack Mitha, et al.
Antiviral Therapy|October 17, 2014
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized studyBisher Akil, Gary Blick, Debbie P Hagins, et al.
AIDS (London, England)|December 15, 2017
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone healthGrace A McComsey, Sergio Lupo, David Parks, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Journal of Acquired Immune Deficiency Syndromes (1999)|December 7, 2019
Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir UseMelissa Crawford, Jean van Wyk, Michael Aboud, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.
Antiviral Therapy|April 13, 2017
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb studyBenoît Trottier, Jordan E Lake, Ken Logue, et al.
Antiviral Therapy|September 14, 2017
Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb studyBenoît Trottier, Jordan E Lake, Ken Logue, et al.
British Journal of Clinical Pharmacology|February 5, 2023
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studiesRashmi Mehta, Chakradhar V Lagishetty, Konstantinos Angelis, et al.
The Journal of Antimicrobial Chemotherapy|July 29, 2025
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeksParul Patel, Ana Milinkovic, Richard Grove, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2022
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2Josep M Llibre, Luis Fernando López Cortés, Alicia Aylott, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b studySamit R Joshi, Mar Masiá, Essack Mitha, et al.
Antiviral Therapy|October 17, 2014
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized studyBisher Akil, Gary Blick, Debbie P Hagins, et al.
AIDS (London, England)|December 15, 2017
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone healthGrace A McComsey, Sergio Lupo, David Parks, et al.
Pageof 8